In January 2026, the US Food and Drug Administration (FDA) announced an important update regarding the safety labeling of certain glucagon-like peptide-1 receptor agonist medications, commonly known as GLP-1 RAs. After completing a comprehensive scientific review, the FDA determined that these medications are not associated with an increased risk of suicidal ideation or suicidal behavior. As a result, the agency is requesting the removal of related warnings from the prescribing information of specific GLP-1 RA products used for weight management.
This decision represents a significant clarification for health care professionals and patients who rely on these medications for the treatment of obesity, overweight, and type 2 diabetes mellitus. It also reflects the FDA’s ongoing commitment to evidence-based drug safety communication.
GLP-1 receptor agonists are a class of medications that mimic the action of a naturally occurring hormone called glucagon-like peptide-1. This hormone is released by the intestine after eating and plays a key role in regulating blood sugar levels and appetite. By enhancing insulin secretion, reducing glucagon release, slowing gastric emptying, and acting on appetite centers in the brain, GLP-1 RAs help patients improve glycemic control and reduce food intake.
The FDA first approved a GLP-1 receptor agonist in 2005 as an adjunct therapy for patients with type 2 diabetes mellitus. Since then, multiple drugs in this class have entered the market, with some approved specifically for chronic weight management in individuals with obesity or overweight.
Among the most well known GLP-1 RA medications are liraglutide, semaglutide, and tirzepatide. These active ingredients are marketed under brand names such as Saxenda, Wegovy, and Zepbound for weight reduction. Other GLP-1 RA products are approved primarily for blood sugar control in diabetes.
At the time of approval for weight loss indications, Saxenda, Wegovy, and Zepbound included warnings in the Warnings and Precautions section of their labeling regarding a potential risk of suicidal ideation and suicidal behavior. These warnings were not unique to GLP-1 receptor agonists.
Historically, many weight loss medications have carried similar language due to reports of psychiatric adverse events associated with older drugs studied or used for obesity management. As a result, cautionary language related to mood changes, depression, and suicidal thoughts became common across the category, even when direct causal links were not well established.
Notably, GLP-1 receptor agonists approved solely for diabetes treatment did not include similar warnings, creating inconsistency across labeling for drugs within the same class.
In July 2023, the FDA initiated a more detailed investigation after receiving postmarketing reports of suicidal ideation and suicidal behavior in patients taking GLP-1 receptor agonist medications. These reports raised questions about whether the observed events were related to the medications themselves or reflected underlying mental health conditions commonly associated with obesity and diabetes.
The FDA first conducted a preliminary review of available data, including clinical trial outcomes, observational studies, and individual case reports. The agency shared early findings in a Drug Safety Communication released in January 2024. That initial analysis did not show a clear association between GLP-1 RA use and suicidal behavior, but the limited number of reported events created uncertainty.
To address this uncertainty, the FDA undertook a comprehensive and methodologically rigorous evaluation using multiple data sources.
One of the key components of the FDA’s assessment was a large meta-analysis of placebo-controlled clinical trials conducted across GLP-1 RA drug development programs. This analysis included 91 trials involving a total of 107,910 patients.
Of these participants, 60,338 received a GLP-1 receptor agonist and 47,572 received a placebo. The meta-analysis compared rates of suicidal ideation, suicidal behavior, and other psychiatric adverse events between the two groups.
The results showed no increased risk of suicidal ideation or behavior among patients treated with GLP-1 receptor agonists compared with those receiving placebo. Additionally, the analysis found no elevated risk for related psychiatric outcomes such as depression, anxiety, irritability, or psychosis.
These findings significantly improved the precision of the risk estimate and helped address concerns raised by earlier, smaller studies.
In addition to clinical trial data, the FDA analyzed real-world evidence using administrative health care claims from the FDA Sentinel System. This retrospective cohort study compared new users of GLP-1 receptor agonists with new users of sodium-glucose cotransporter 2 inhibitors, another class of medications commonly prescribed for type 2 diabetes.
The study included more than 2.2 million patients from 10 data partners, covering the period from October 2015 through September 2023. Approximately 1.16 million patients initiated GLP-1 RA therapy, while about 1.08 million initiated SGLT2 inhibitor therapy.
After adjusting for baseline differences and potential confounding factors, the FDA found no increased risk of intentional self-harm among GLP-1 RA users compared with SGLT2 inhibitor users. This finding remained consistent in subgroups of patients who had both type 2 diabetes mellitus and obesity.
The FDA also reviewed published observational studies and pooled analyses examining the relationship between GLP-1 receptor agonists and suicidal ideation or behavior. When considered together, the totality of this evidence did not support a causal relationship between GLP-1 RA use and suicidal outcomes.
By integrating data from randomized trials, large observational cohorts, and published research, the FDA concluded that the available evidence consistently showed no increased psychiatric risk attributable to these medications.
Based on these findings, the FDA is now requesting that manufacturers remove language related to suicidal ideation and suicidal behavior from the labeling of GLP-1 receptor agonist medications that currently include such warnings. This request applies specifically to Saxenda, Wegovy, and Zepbound.
The agency stated that this action will promote consistent messaging across the labeling of all FDA approved GLP-1 receptor agonist medications, regardless of whether they are indicated for weight loss or diabetes management.
Importantly, this change does not mean that mental health symptoms should be ignored. Rather, it reflects the absence of evidence linking GLP-1 RAs to an increased risk of suicidal behavior when used as directed.
Patients currently taking GLP-1 receptor agonist medications should continue using them as prescribed by their health care professionals. The FDA emphasizes that individuals should not stop or change their medication without medical guidance.
Patients and caregivers are encouraged to remain attentive to changes in mood, behavior, or mental health. Any new or worsening symptoms of depression, suicidal thoughts, or unusual behavioral changes should be promptly discussed with a health care provider.
For individuals experiencing emotional distress or suicidal thoughts, immediate help is available through the Suicide and Crisis Lifeline by calling or texting 988, or by visiting the 988 Lifeline website. This service provides free, confidential support 24 hours a day.
Health care professionals should be aware of the FDA’s findings and the request to remove suicidal ideation warnings from certain GLP-1 RA labels. Clinicians should be prepared to discuss these findings with patients who may have concerns about psychiatric safety.
If a patient discloses suicidal ideation or behavior, appropriate referral to mental health services remains essential. The absence of a drug-related risk does not eliminate the need for careful mental health screening and support, especially in populations with higher baseline rates of depression or anxiety.
The FDA continues to encourage the reporting of adverse events related to GLP-1 receptor agonists through the FDA MedWatch program. Reports from patients and health care professionals play a critical role in identifying potential safety issues and ensuring continued oversight of approved medications.
Patients and clinicians can submit reports online, by phone, or by mail using MedWatch reporting forms.
The FDA’s January 2026 announcement provides reassurance regarding the psychiatric safety of GLP-1 receptor agonist medications. After an extensive and multifaceted review, the agency found no evidence of increased suicidal ideation or behavior associated with these drugs.
The decision to request removal of related warnings from labeling underscores the importance of relying on high quality evidence when evaluating drug risks. For patients managing obesity or type 2 diabetes, this update supports continued confidence in the use of GLP-1 receptor agonists as part of a comprehensive treatment plan.
US Food and Drug Administration.
This article is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always seek the advice of a qualified health care professional regarding any medical condition, medication, or treatment decision. Never disregard professional medical advice or delay seeking care because of information presented in this article.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.